Skip to main content
Clinical Trials/CTRI/2025/03/082978
CTRI/2025/03/082978RecruitingPhase 3 4

Comparison of C-MAC Miller Size 0 Blade and C-MAC Macintosh Size 0 Blade for Intubation in Preterm Infants & Neonates: A Randomised Controlled Study

Not provided1 site in 1 country50 target enrollmentStarted: April 15, 2025Last updated:

Trial Snapshot

Phase
Phase 3 4
Status
Recruiting
Enrollment
50
Locations
1
Primary Endpoint
Time to Intubation (TTI): Time from insertion of the blade in the mouth to the passage of the endotracheal tube through the vocal cords.

Study Overview

Brief Summary

Neonatal airway management presents unique challenges due to the anatomical and physiological differences in preterm infants and neonates, such as a proportionally larger tongue, anterior larynx, and narrower airway. These features make intubation technically demanding and necessitate specialized tools. The C-MAC video laryngoscope, with its Miller and Macintosh blades, has been extensively used in adult and pediatric airway management. However, there is limited evidence comparing these blades for intubation in preterm infants and neonates. This randomised controlled study aims to evaluate and compare the effectiveness of the C-MAC Miller size 0 blade with the C-MAC Macintosh size 0 blade for endotracheal intubation in this population. After performing a pre-anesthetic check-up and obtaining consent, eligible participants will be randomised into two groups: Group Miller: Intubation with the C-MAC Miller size 0 blade and Group Macintosh: Intubation with the C-MAC Macintosh size 0 blade. In the operation theatre, routine monitors (ECG, SpOâ‚‚, NIBP) will be applied, and general anesthesia will be induced with sevoflurane. After adequate depth of anesthesia is achieved, atracurium (0.5 mg/kg) will be administered, and manual ventilation will be provided. Intubation will then be performed using the allocated blade by an experienced paediatric anaesthesiologist, following standardized techniques. The primary outcome will be the time to intubation (TTI) and secondary outcomes will include: Total time for the procedure (TTP), Glottic visualization quality (POGO score), Intubation attempts, Ease of blade, and ETT insertion and adverse events, such as desaturation (SpOâ‚‚ < 90%) or bradycardia. All intubations will be video-recorded to ensure objectivity during outcome analysis. If intubation fails after two attempts, an alternative blade will be used, and the event will be documented as a failure. This study aims to identify the optimal blade design for preterm neonatal intubation by analysing efficiency, ease of use, and safety parameters, contributing to improved clinical practices in neonatal airway management.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
0.00 Day(s) to 1.00 Month(s) (—)
Sex
All

Inclusion Criteria

  • Preterm infants & neonates [from birth till 60 weeks post conceptional age (PCA) or 1 month of age].

Exclusion Criteria

  • Neonates with known craniofacial abnormalities or congenital airway malformations.
  • History of difficult intubation.
  • Hemodynamic instability or conditions contraindicating elective intubation.

Outcomes

Primary Outcomes

Time to Intubation (TTI): Time from insertion of the blade in the mouth to the passage of the endotracheal tube through the vocal cords.

Time Frame: From the time of induction of anaesthesia till endotracheal intubation is completed. (usually 5-10 minutes from start of anaesthesia induction)

Secondary Outcomes

  • 1.Time to Best Glottic View (TTGV): Time from insertion of the blade in the mouth to achieving the best possible glottic view.(2.Time to Procedure (TTP): Time from insertion of the blade in the mouth till square shaped etCO2 tracing is seen in the monitor.)

Investigators

Sponsor
Not provided
Responsible Party
Principal Investigator
Principal Investigator

Renu Sinha

All India Institute of Medical Sciences, New Delhi

Study Sites (1)

Loading locations...

Similar Trials

Comparison of Two Blades (C-MAC Miller and... | Clinical Trial